thiamazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1745	60-56-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: methimazole methylimidazolethiol thyrozol thymidazole thymidazol thycapzol thiamazole tapazole methymazol	A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme. Molecular weight: 114.17 Formula: C4H6N2S CLOGP: -0.34 LIPINSKI: 0 HAC: 2 HDO: 1 TPSA: 15.27 ALOGS: -1 ROTB: 0 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

methimazole
methylimidazolethiol
thyrozol
thymidazole
thymidazol
thycapzol
thiamazole
tapazole
methymazol

A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme.

Molecular weight: 114.17
Formula: C4H6N2S
CLOGP: -0.34
LIPINSKI: 0
HAC: 2
HDO: 1
TPSA: 15.27
ALOGS: -1
ROTB: 0

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
10	mg	O

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	8.76 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Hosey CM, Chan R, Benet LZ
BA (Bioavailability)	93 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.86 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	3.70 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.40 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
June 21, 1950	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperthyroidism	393.53	13.81	126	8680	13226	56270035
Agranulocytosis	379.28	13.81	140	8666	22519	56260742
Thyrotoxic crisis	277.92	13.81	55	8751	776	56282485
Hypothyroidism	70.98	13.81	54	8752	38142	56245119
Antithyroid arthritis syndrome	66.56	13.81	9	8797	4	56283257
Choanal atresia	59.34	13.81	9	8797	20	56283241
Exophthalmos	45.55	13.81	14	8792	1278	56281983
Neutropenia	41.18	13.81	82	8724	158085	56125176
Blood thyroid stimulating hormone decreased	38.47	13.81	17	8789	4316	56278945
Rheumatoid arthritis	37.99	13.81	7	8799	382597	55900664
Drug-induced liver injury	34.05	13.81	34	8772	34428	56248833
Jaundice cholestatic	31.59	13.81	16	8790	5503	56277758
Goitre	31.44	13.81	16	8790	5557	56277704
Dysmorphism	30.90	13.81	12	8794	2201	56281060
Insulin autoimmune syndrome	30.28	13.81	6	8800	85	56283176
Toxic nodular goitre	29.86	13.81	5	8801	25	56283236
Anti-neutrophil cytoplasmic antibody positive vasculitis	29.11	13.81	12	8794	2571	56280690
Thyroxine free increased	29.02	13.81	9	8797	846	56282415
Cardiac arrest	26.45	13.81	48	8758	86266	56196995
Pulmonary alveolar haemorrhage	26.28	13.81	13	8793	4251	56279010
Mucocutaneous candidiasis	25.77	13.81	4	8802	11	56283250
Aplasia cutis congenita	25.35	13.81	5	8801	69	56283192
Polyarthritis	24.76	13.81	16	8790	8712	56274549
Endocrine ophthalmopathy	24.43	13.81	7	8799	501	56282760
Drug interaction	24.24	13.81	80	8726	209675	56073586
Drug intolerance	23.91	13.81	6	8800	264812	56018449
Oropharyngeal pain	23.67	13.81	45	8761	83743	56199518
Stevens-Johnson syndrome	23.57	13.81	23	8783	22640	56260621
Cardiac failure	21.86	13.81	43	8763	82050	56201211
Arthropathy	21.34	13.81	3	8803	200272	56082989
Eosinophilic pleural effusion	20.73	13.81	4	8802	49	56283212
Respiratory syncytial virus infection	20.57	13.81	12	8794	5449	56277812
Acquired epidermolysis bullosa	20.23	13.81	4	8802	56	56283205
Thyroid disorder	20.11	13.81	17	8789	13921	56269340
Toxic goitre	20.00	13.81	3	8803	6	56283255
Hypoglycaemia	19.64	13.81	33	8773	55782	56227479
Sopor	19.49	13.81	20	8786	20902	56262359
Thyroidectomy	19.44	13.81	7	8799	1042	56282219
Functional residual capacity increased	19.23	13.81	4	8802	73	56283188
Autoimmune neutropenia	19.18	13.81	4	8802	74	56283187
Thyroid haemorrhage	19.13	13.81	4	8802	75	56283186
Electrocardiogram QT prolonged	18.84	13.81	32	8774	54556	56228705
Hepatitis cholestatic	18.79	13.81	12	8794	6402	56276859
Symptom masked	18.40	13.81	6	8800	663	56282598
Multiple organ dysfunction syndrome	18.30	13.81	31	8775	52739	56230522
Hypersensitivity vasculitis	18.23	13.81	10	8796	4038	56279223
Atrial fibrillation	17.79	13.81	47	8759	108850	56174411
Clinodactyly	17.47	13.81	4	8802	116	56283145
Contraindicated product administered	17.23	13.81	4	8802	186282	56096979
Therapeutic product effect decreased	17.00	13.81	3	8803	169449	56113812
Thyroxine free abnormal	16.93	13.81	3	8803	22	56283239
Neuroglycopenia	16.67	13.81	5	8801	420	56282841
Exposure during pregnancy	16.63	13.81	53	8753	136289	56146972
Systemic lupus erythematosus	16.40	13.81	4	8802	180074	56103187
Metabolic function test abnormal	15.81	13.81	4	8802	178	56283083
Febrile neutropenia	15.68	13.81	44	8762	105501	56177760
Spigelian hernia	15.68	13.81	3	8803	35	56283226
Microscopic polyangiitis	15.38	13.81	4	8802	199	56283062
Kidney transplant rejection	15.19	13.81	9	8797	4204	56279057
Systemic candida	15.06	13.81	8	8798	3033	56280228
Tri-iodothyronine free increased	14.95	13.81	4	8802	222	56283039
Thyroiditis	14.90	13.81	7	8799	2045	56281216
Mucosal erosion	14.46	13.81	6	8800	1305	56281956
Renal infarct	14.16	13.81	6	8800	1376	56281885
Acute generalised exanthematous pustulosis	14.16	13.81	12	8794	9857	56273404
Thyroid function test abnormal	14.15	13.81	8	8798	3425	56279836
Hepatitis	13.88	13.81	22	8784	35419	56247842

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperthyroidism	389.17	18.72	110	3859	9521	31683854
Agranulocytosis	85.16	18.72	45	3924	21202	31672173
Thyrotoxic crisis	65.58	18.72	14	3955	368	31693007
Thyrotoxic periodic paralysis	63.37	18.72	11	3958	91	31693284
Hypothyroidism	60.74	18.72	34	3935	17913	31675462
Kounis syndrome	46.06	18.72	15	3954	2069	31691306
Polymerase chain reaction	43.46	18.72	8	3961	95	31693280
Goitre	33.56	18.72	11	3958	1548	31691827
Albumin urine present	33.18	18.72	8	3961	366	31693009
Exomphalos	33.08	18.72	7	3962	176	31693199
Urine leukocyte esterase positive	31.43	18.72	8	3961	458	31692917
Cholestatic liver injury	31.12	18.72	11	3958	1943	31691432
Product administered to patient of inappropriate age	30.53	18.72	12	3957	2845	31690530
Thyroiditis	30.13	18.72	11	3958	2132	31691243
Haemoglobinuria	29.51	18.72	8	3961	586	31692789
Mouth swelling	28.80	18.72	10	3959	1676	31691699
Pericarditis fungal	28.24	18.72	6	3963	154	31693221
Urinary bladder rupture	25.27	18.72	5	3964	89	31693286
Urine ketone body present	24.76	18.72	8	3961	1076	31692299
Autoimmune thyroiditis	24.61	18.72	8	3961	1097	31692278
Respiratory tract haemorrhage	24.28	18.72	8	3961	1143	31692232
Glycosuria	23.96	18.72	8	3961	1192	31692183
Axial spondyloarthritis	23.36	18.72	6	3963	356	31693019
Loss of proprioception	23.15	18.72	6	3963	369	31693006
Tracheo-oesophageal fistula	22.16	18.72	6	3963	437	31692938
Blood cyanide increased	22.01	18.72	4	3965	44	31693331
Coagulation time shortened	20.90	18.72	5	3964	221	31693154
Drug-induced liver injury	20.70	18.72	20	3949	24343	31669032
Blood sodium decreased	19.89	18.72	16	3953	15299	31678076

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperthyroidism	660.43	13.24	208	11361	19883	70896992
Agranulocytosis	410.43	13.24	176	11393	40122	70876753
Thyrotoxic crisis	323.28	13.24	67	11502	1153	70915722
Hypothyroidism	117.46	13.24	80	11489	45675	70871200
Antithyroid arthritis syndrome	66.19	13.24	9	11560	4	70916871
Thyrotoxic periodic paralysis	59.83	13.24	11	11558	97	70916778
Goitre	50.63	13.24	22	11547	5144	70911731
Exophthalmos	50.19	13.24	16	11553	1578	70915297
Drug-induced liver injury	45.84	13.24	51	11518	56062	70860813
Anti-neutrophil cytoplasmic antibody positive vasculitis	42.26	13.24	17	11552	3280	70913595
Polymerase chain reaction	39.43	13.24	8	11561	123	70916752
Endocrine ophthalmopathy	37.07	13.24	10	11559	549	70916326
Kounis syndrome	34.98	13.24	15	11554	3396	70913479
Product administered to patient of inappropriate age	32.93	13.24	16	11553	4827	70912048
Thyroiditis	32.56	13.24	15	11554	4021	70912854
Jaundice cholestatic	30.78	13.24	19	11550	9165	70907710
Cardiac arrest	30.43	13.24	75	11494	159759	70757116
Cardiac failure	30.17	13.24	70	11499	143471	70773404
Blood thyroid stimulating hormone decreased	28.27	13.24	15	11554	5439	70911436
Neutropenia	28.11	13.24	99	11470	257057	70659818
Albumin urine present	26.38	13.24	8	11561	669	70916206
Pericarditis fungal	26.05	13.24	6	11563	171	70916704
Thyroxine free increased	25.71	13.24	9	11560	1184	70915691
Polyarthritis	25.67	13.24	18	11551	10738	70906137
Haemoglobinuria	25.50	13.24	8	11561	749	70916126
Rheumatoid arthritis	25.40	13.24	8	11561	291797	70625078
Hepatitis cholestatic	25.26	13.24	19	11550	12631	70904244
Toxic goitre	24.26	13.24	4	11565	17	70916858
Autoimmune thyroiditis	24.06	13.24	12	11557	3830	70913045
Drug intolerance	23.98	13.24	4	11565	225683	70691192
Urinary bladder rupture	22.99	13.24	5	11564	109	70916766
Drug interaction	22.53	13.24	122	11447	381319	70535556
Pulseless electrical activity	22.37	13.24	18	11551	13197	70903678
Atrial fibrillation	21.90	13.24	73	11496	184275	70732600
Cardiogenic shock	21.44	13.24	28	11541	36279	70880596
Hepatitis	21.32	13.24	33	11536	49947	70866928
Insulin autoimmune syndrome	21.26	13.24	6	11563	390	70916485
Blood cyanide increased	20.95	13.24	4	11565	44	70916831
Toxic nodular goitre	20.56	13.24	4	11565	49	70916826
Cholestatic liver injury	20.31	13.24	11	11558	4157	70912718
Electrocardiogram QT prolonged	20.09	13.24	43	11526	83474	70833401
Pulmonary alveolar haemorrhage	19.44	13.24	15	11554	10354	70906521
Respiratory tract haemorrhage	19.21	13.24	8	11561	1684	70915191
Functional residual capacity increased	18.87	13.24	4	11565	77	70916798
Urine leukocyte esterase positive	18.82	13.24	10	11559	3635	70913240
Tonsillitis	18.81	13.24	12	11557	6128	70910747
Acquired epidermolysis bullosa	18.45	13.24	4	11565	86	70916789
Completed suicide	18.42	13.24	7	11562	227128	70689747
Mucocutaneous candidiasis	18.40	13.24	4	11565	87	70916788
Sopor	18.29	13.24	24	11545	31243	70885632
Thyroid haemorrhage	17.87	13.24	4	11565	100	70916775
Glycosuria	17.43	13.24	8	11561	2127	70914748
Jaundice	17.20	13.24	30	11539	50078	70866797
Oropharyngeal pain	17.06	13.24	44	11525	96266	70820609
Coagulation time shortened	16.69	13.24	5	11564	401	70916474
Thyroidectomy	16.62	13.24	6	11563	863	70916012
Respiratory syncytial virus infection	16.41	13.24	12	11557	7643	70909232
Neuroglycopenia	16.39	13.24	5	11564	426	70916449
Thyroid dermatopathy	16.26	13.24	3	11566	27	70916848
Tonsillitis bacterial	15.99	13.24	4	11565	163	70916712
Ventricular septal defect	15.75	13.24	5	11564	486	70916389
Cholestasis	15.58	13.24	28	11541	47844	70869031
Antineutrophil cytoplasmic antibody	15.48	13.24	3	11566	36	70916839
Hypersensitivity vasculitis	15.32	13.24	11	11558	6811	70910064
Mouth swelling	15.27	13.24	10	11559	5339	70911536
Arthropathy	15.20	13.24	3	11566	150054	70766821
Metabolic function test abnormal	15.19	13.24	4	11565	200	70916675
Immune-mediated hepatitis	15.19	13.24	8	11561	2858	70914017
Pericardial haemorrhage	14.73	13.24	9	11560	4259	70912616
Tri-iodothyronine increased	14.68	13.24	4	11565	228	70916647
Symptom masked	14.50	13.24	6	11563	1243	70915632
Tri-iodothyronine free increased	14.19	13.24	4	11565	259	70916616
Urine ketone body present	13.96	13.24	8	11561	3371	70913504
Pure white cell aplasia	13.73	13.24	3	11566	67	70916808
Hypoglycaemia	13.62	13.24	40	11529	94324	70822551
Bradycardia	13.61	13.24	48	11521	124567	70792308
Eosinophilic pleural effusion	13.52	13.24	4	11565	307	70916568

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	H03BB02	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS THYROID THERAPY ANTITHYROID PREPARATIONS Sulfur-containing imidazole derivatives
ATC	H03BB52	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS THYROID THERAPY ANTITHYROID PREPARATIONS Sulfur-containing imidazole derivatives
MeSH PA	D013956	Antithyroid Agents
MeSH PA	D006727	Hormone Antagonists
FDA MoA	N0000175917	Thyroid Hormone Synthesis Inhibitors
FDA EPC	N0000175918	Thyroid Hormone Synthesis Inhibitor
CHEBI has role	CHEBI:50671	antithyroid drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hyperthyroidism	indication	34486009	DOID:7998
Thyrotoxic crisis	off-label use	29028009	DOID:12837
Agranulocytosis	contraindication	17182001	DOID:12987
Hypothyroidism	contraindication	40930008	DOID:1459
Factor II deficiency	contraindication	73975000
Leukopenia	contraindication	84828003	DOID:615
Pancytopenia	contraindication	127034005	DOID:12450
Liver function tests abnormal	contraindication	166603001
Drug-induced hepatitis	contraindication	235876009
Pregnancy, function	contraindication	289908002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Bone marrow depression	contraindication	307762000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

Product	Applicant	Ingredients
Felimazole	Dechra, Ltd.	1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.7	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Thyroid peroxidase	Enzyme	P07202	PERT_HUMAN	INHIBITOR	IC50	5.57	WOMBAT-PK	CHEMBL
Lactoperoxidase	Enzyme	P22079	PERL_HUMAN		IC50	4.93	CHEMBL
Lactoperoxidase	Enzyme		PERL_BOVIN		IC50	5.08	CHEMBL
Dopamine beta-hydroxylase	Enzyme		DOPO_BOVIN		Ki	4.35	CHEMBL

External reference:

ID	Source
4017434	VUID
N0000145822	NUI
D00401	KEGG_DRUG
4017434	VANDF
C0025644	UMLSCUI
CHEBI:50673	CHEBI
MMZ	PDB_CHEM_ID
CHEMBL1515	ChEMBL_ID
DB00763	DRUGBANK_ID
6649	IUPHAR_LIGAND_ID
554Z48XN5E	UNII
1349907	PUBCHEM_CID
224936	RXNORM
2293	MMSL
31962	MMSL
5073	MMSL
d00290	MMSL
002139	NDDF
37656002	SNOMEDCT_US
404864000	SNOMEDCT_US
D008713	MESH_DESCRIPTOR_UI
4198	INN_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0205	TABLET	5 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0210	TABLET	10 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	23155-070	TABLET	5 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	23155-070	TABLET	5 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	23155-071	TABLET	10 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	23155-071	TABLET	10 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	42254-008	TABLET	5 mg	ORAL	ANDA	18 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	42254-009	TABLET	10 mg	ORAL	ANDA	18 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	49884-640	TABLET	5 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	49884-640	TABLET	5 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	49884-641	TABLET	10 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	49884-641	TABLET	10 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	50090-2366	TABLET	5 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3334	TABLET	5 mg	ORAL	ANDA	20 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	51293-820	TABLET	5 mg	ORAL	ANDA	18 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	51293-821	TABLET	10 mg	ORAL	ANDA	18 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	53808-0850	TABLET	10 mg	ORAL	ANDA	18 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	53808-0949	TABLET	10 mg	ORAL	ANDA	18 sections
METHIMAZOLE	HUMAN PRESCRIPTION DRUG LABEL	1	53808-1044	TABLET	10 mg	ORAL	ANDA	18 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5135	TABLET	10 mg	ORAL	ANDA	18 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	54868-6071	TABLET	5 mg	ORAL	ANDA	18 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	60429-380	TABLET	5 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	60429-380	TABLET	5 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	60429-381	TABLET	10 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	60429-381	TABLET	10 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	60687-357	TABLET	5 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	60687-357	TABLET	5 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	60687-370	TABLET	10 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	60687-370	TABLET	10 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	60687-669	TABLET	5 mg	ORAL	ANDA	20 sections